Cited by 82

Transcription activation of FLRG and follistatin by activin A, through smad proteins, participates in a negative feedback loop to modulate activin a function.

Bartholin, Laurent, Maguer-Satta, Véronique, Hayette, Sandrine, Martel, Sylvie, Gadoux, Mylène, Corbo, Laura, Magaud, Jean-Pierre, Rimokh, Ruth·2002·Oncogene

Abstract

Signaling of TGFbeta family members such as activin is tightly regulated by soluble binding proteins. Follistatin binds to activin A with high affinity, and prevents activin binding to its own receptors, thereby blocking its signaling. We previously identified FLRG gene from a B-cell leukemia carrying a t(11;19)(q13;p13) translocation. We and others have already shown that FLRG, which is highly homologous to follistatin, may be involved in the regulation of the activin function through its binding to activin. In this study, we found that, like follistatin, FLRG protein inhibited activin A signaling as demonstrated by the use of a transcriptional reporter assay, and blocked the activin A-induced growth inhibition of HepG2 cells. We have recently shown that the TGFbeta-induced expression of FLRG occurs at a transcriptional level through the action of Smad proteins. Here we show that activin A increases FLRG and follistatin at both the mRNA and protein levels. We found that Smad proteins are involved in the activin A-induced transcription activation of FLRG and follistatin. Finally we demonstrate that FLRG protein regulates its own activin-induced expression. In conclusion, activin A induces FLRG and follistatin expression. This observation, in conjunction with the antagonistic effect of FLRG and follistatin on activin signaling, indicates that these two proteins participate in a negative feedback loop which regulates the activin function.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1205294

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • When ligand levels diminish, attenuators also diminish and receptors increase; signaling re-boot induces negative regulators, as observed for follistatin and follistatin-like, secondarily diminishing the intensity of age-elevated pathways.

    “When the levels of ligand(s) diminish, attenuators also diminish, and receptor(s) increase [62, 63]; signaling re-boot induces negative regulators, as we observed for follistatin and follistatin-like, secondarily diminishing the intensity of age-elevated pathways [64–66].”

Cites

Flagged first, then by citations

Research works printed but not linked: 42

  1. Bartholin L, Maguer-Satta V, Hayette S, Martel S, Gadoux M, Bertrand S, Corbo L, Lamadon C, Morera A, Magaud J, Rimokh R . 2001 Oncogene 20: 5409–5419 · DOI
  2. Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Bottinger EP . 2000 Genes Dev. 14: 187–197 · DOI
  3. Brodin G, Ahgren A, ten Dijke P, Heldin CH, Heuchel R . 2000 J. Biol. Chem. 275: 29023–29030 · DOI
  4. de Winter JP, ten Dijke P, de Vries CJ, van Achterberg TA, Sugino H, de Waele P, Huylebroeck D, Verschueren K, van den Eijnden-van Raaij AJ . 1996 Mol. Cell. Endocrinol. 116: 105–114 · DOI
  5. Denissova NG, Pouponnot C, Long J, He D, Liu F . 2000 Proc. Natl. Acad. Sci. USA 97: 6397–6402 · DOI
  6. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM . 1998 EMBO J. 17: 3091–3100 · DOI
  7. DePaolo LV . 1997 Proc. Soc. Exp. Biol. Med. 214: 328–339 · DOI
  8. Derynck R, Zhang Y, Feng XH . 1998 Cell 95: 737–740 · DOI
  9. Fainsod A, Deissler K, Yelin R, Marom K, Epstein M, Pillemer G, Steinbeisser H, Blum M . 1997 Mech. Dev. 63: 39–50 · DOI
  10. Gamer LW, Wolfman NM, Celeste AJ, Hattersley G, Hewick R, Rosen V . 1999 Dev. Biol. 208: 222–232 · DOI
  11. Gazzerro E, Gangji V, Canalis E . 1998 J. Clin. Invest. 102: 2106–2114 · DOI
  12. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrone Jr MA, Wrana JL, Falb D . 1997 Cell 89: 1165–1173 · DOI
  13. Hayette S, Gadoux M, Martel S, Bertrand S, Tigaud I, Magaud JP, Rimokh R . 1998 Oncogene 16: 2949–2954 · DOI
  14. Iemura S, Yamamoto TS, Takagi C, Uchiyama H, Natsume T, Shimasaki S, Sugino H, Ueno N . 1998 Proc. Natl. Acad. Sci. USA 95: 9337–9342 · DOI
  15. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K . 1997 Nature 389: 622–626 · DOI
  16. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J . 1996 Nature 383: 832–836 · DOI
  17. Lebrun JJ, Takabe K, Chen Y, Vale W . 1999 Mol. Endocrinol. 13: 15–23 · DOI
  18. Maguer-Satta V, Bartholin L, Jeanpierre S, Gadoux M, Bertrand S, Martel S, Magaud JP, Rimokh R . 2001 Exp. Hematol. 29: 301–308 · DOI
  19. Massague J, Wotton D . 2000 EMBO J. 19: 1745–1754 · DOI
  20. Moustakas A, Kardassis D . 1998 Proc. Natl. Acad. Sci. USA 95: 6733–6738 · DOI
  21. Nagarajan RP, Zhang J, Li W, Chen Y . 1999 J. Biol. Chem. 274: 33412–33418 · DOI
  22. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H . 1990 Science 247: 836–838 · DOI
  23. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P . 1997 Nature 389: 631–635 · DOI
  24. Pereira RC, Economides AN, Canalis E . 2000 Endocrinology 141: 4558–4563 · DOI
  25. Phillips DJ . 2000 Bioessays 22: 689–696 · DOI
  26. Phillips DJ, de Kretser DM . 1998 Front. Neuroendocrinol. 19: 287–322 · DOI
  27. Piek E, Heldin CH, Ten Dijke P . 1999 Faseb J. 13: 2105–2124 · DOI
  28. Reddi AH . 2001 Arthritis Res. 3: 1–5 · DOI
  29. Russell CE, Hedger MP, Brauman JN, de Kretser DM, Phillips DJ . 1999 Mol. Cell. Endocrinol. 148: 129–136 · DOI
  30. Schwall RH, Robbins K, Jardieu P, Chang L, Lai C, Terrell TG . 1993 Hepatology 18: 347–356 · DOI
  31. Shimasaki S, Koga M, Esch F, Cooksey K, Mercado M, Koba A, Ueno N, Ying SY, Ling N, Guillemin R . 1988 Proc. Natl. Acad. Sci. USA 85: 4218–4222 · DOI · Paper page
  32. Smith WC . 1999 Trends Genet. 15: 3–5 · DOI
  33. Takase M, Imamura T, Sampath TK, Takeda K, Ichijo H, Miyazono K, Kawabata M . 1998 Biochem. Biophys. Res. Commun. 244: 26–29 · DOI
  34. ten Dijke P, Miyazono K, Heldin CH . 2000 Trends Biochem. Sci. 25: 64–70 · DOI
  35. Tsuchida K, Arai KY, Kuramoto Y, Yamakawa N, Hasegawa Y, Sugino H . 2000 J. Biol. Chem. 275: 40788–40796 · DOI
  36. Ulloa L, Doody J, Massague J . 1999 Nature 397: 710–713 · DOI
  37. Vindevoghel L, Lechleider RJ, Kon A, de Caestecker MP, Uitto J, Roberts AB, Mauviel A . 1998 Proc. Natl. Acad. Sci. USA 95: 14769–14774 · DOI
  38. Wrana JL . 2000 Cell 100: 189–192 · DOI
  39. Yamashita T, Takahashi S, Ogata E . 1992 Blood 79: 304–307 · DOI
  40. Yasuda H, Mine T, Shibata H, Eto Y, Hasegawa Y, Takeuchi T, Asano S, Kojima I . 1993 J. Clin. Invest. 92: 1491–1496 · DOI
  41. Ying SY, Zhang Z, Furst B, Batres Y, Huang G, Li G . 1997 Proc. Soc. Exp. Biol. Med. 214: 114–122 · DOI
  42. Zhang Y, Feng X, We R, Derynck R . 1996 Nature 383: 168–172 · DOI

Cited by

Sorted by citations

Authors
Bartholin, L., Maguer-Satta, V., Hayette, S., Martel, S., Gadoux, M., Corbo, L., Magaud, J.-P., & Rimokh, R.
Venue
Oncogene
Published
2002-03-28
Volume
21
Issue
14
Pages
2227-2235
ISSN
  • 0950-9232
  • 1476-5594
Cited by
82
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review